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AbstrACt
Introduction Services are being encouraged to provide 
postdiagnostic treatment to those with dementia but the 
availability of evidence-based interventions following 
diagnosis has not kept pace with increase in demand. To 
address this need, the Journeying through Dementia (JtD) 
intervention was created. A randomised controlled trial 
(RCT), based on a pilot study, is in progress.
Methods and analysis The RCT is a pragmatic, two-
arm, parallel group trial designed to test the clinical and 
cost-effectiveness of JtD compared with usual care. 
Recruitment will be through NHS services, third sector 
organisations and Join Dementia Research. The sample 
size is 486 randomised (243 to usual care and 243 to the 
intervention usual care). Participants can choose to ask 
a friend or relative (supporter) to become involved in the 
study. The primary outcome measure for participants is 
Dementia-Related Quality of Life (DEMQOL), collected at 
baseline and at 8 months’ postrandomisation. Secondary 
outcome measures will be collected from participants and 
supporters at those visits. Participants will also be followed 
up at 12 months’ postrandomisation with a reduced set 
of measures. A process evaluation will be conducted 
through qualitative and fidelity substudies. Analyses will 
compare the two arms of the trial on an intention to treat 
as allocated basis. The primary analyses will compare 
the mean DEMQOL scores of the participants at 8 months 
between the two study arms. A cost-effectiveness analysis 
will consider the incremental cost per Quality Adjusted 
Life Years of the intervention compared with usual care. 
Qualitative and fidelity substudies will be analysed 
through framework analysis and fidelity assessment tools 
respectively.
Ethics and dissemination REC and HRA approval were 
obtained. A Data Monitoring and Ethics Committee has 
been constituted. Dissemination will be via publications, 
conferences and social media. Intervention materials will 
be made open access.
trial registration number ISRCTN17993825.
IntroduCtIon
The impact on the economy, for services and 
for individuals living with dementia and their 
family carers is larger for dementia than for 
all other long-term illnesses in people aged 60 
and over.1 Two thirds of people with dementia 
live in the community, and half of these 
require some form of support.2 As a result, 
dementia research (both for cure and for 
care) in the NHS and social care is important, 
and this is reflected in UK health policy.3 In 
2009, the UK Government announced a 
National Dementia Strategy, which mandated 
strengths and limitations of this study
 ► People living with dementia were involved in de-
veloping the content of the Journeying through 
Dementia (JtD) intervention and are involved in ad-
vising the study.
 ► The JtD intervention includes sessions without sup-
porters present, to help develop independence and 
confidence and is one of the only interventions that 
people with dementia can participate in without 
supporters.
 ► The JtD study will recruit up to 500 participants and 
is therefore one of the largest trials of a psychosocial 
intervention for people with dementia in the UK.
 ► The potential for unblinding of researchers when 
arranging or attending follow-up visits is a limita-
tion but this will be monitored and minimised by not 
sending unblind researchers to visits.
 ► Recruitment is known to be challenging in this 
population but we plan to try multiple pathways 
for recruitment including through services, the Join 
Dementia Research database, promotion and the 
third sector.
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the establishment of memory services and aimed to 
increase the rates of early diagnosis and improve support 
for people in the early stages of dementia.4
The National Audit of Memory Services (2013) found 
there had been a fourfold increase in numbers presenting 
since 2010/2011, and in 2013 49.3% were in the early 
stages of the condition.5 Earlier diagnosis allows individ-
uals to receive treatment earlier and enables the indi-
vidual and memory services to plan more effectively for 
the future.6 Memory services have been strongly encour-
aged to provide postdiagnostic treatment and support,7 8 
but the availability of appropriate evidence-based inter-
ventions has not kept pace with the increase in demand, 
in particular for those with early stages of dementia. The 
lack of appropriate interventions has led to inconsistency 
between Trusts regarding what is being offered to people 
postdiagnosis.
The potential value of psychosocial interventions for 
people in the early stages of dementia is recognised9–12 
and is also driven by the knowledge that a cure for 
dementia is unlikely in the near future. Psychosocial inter-
ventions are diverse but a common theme is that they do 
not involve the use of medication and instead focus on 
supporting people to overcome challenges and maintain 
independence and well-being. However, while there has 
been some shift, the use of psychosocial interventions 
within dementia care has been a neglected area for both 
research and practice.11
There is a growing body of evidence to demonstrate 
how individuals with dementia can be supported to use 
self-management-based techniques (sometimes in combi-
nation with other interventions such as cognitive rehabil-
itation and occupational therapy).13–18 A qualitative study 
of people with dementia who attended a self-manage-
ment programme reported that participants identified 
the opportunity for peer support as being beneficial and 
considered that the programme could be improved by 
greater emphasis being placed on maintaining activities 
and relationships and improving positive well-being.19 
The Healthbridge evaluation20 and the Mental Health 
Foundation evaluation21 found evidence that people with 
dementia and their carers can benefit from receiving 
group-based peer support.
The Journeying through Dementia (JtD) intervention 
was developed from the Lifestyle Matters programme 
and a pilot study was conducted to examine the feasi-
bility of a future population-based larger trial of this 
intervention.22 The intervention was found to be accept-
able to both people with dementia and their carers. 
Reported benefits included increased confidence and 
self-efficacy, engagement in activities and re-engagement 
with fun and friendships.22 The intervention is manual-
ised, based on occupational therapy principles, and is 
designed to support independence and well-being. The 
intervention incorporates elements of self-management 
and group-based peer support and has been designed to 
improve the quality of life for people in the early stages 
of dementia.
The JtD randomised controlled trial (RCT) will test 
the clinical and cost effectiveness of the JtD intervention. 
Funding was obtained through the National Institute of 
Health Research (NIHR) Health Technology Assessment 
(HTA) theme to conduct the RCT. This paper describes 
the research protocol for undertaking the RCT which 
started recruitment in November 2016.
AIMs And objECtIvEs
The primary aim of the JtD trial is to determine the clin-
ical and cost-effectiveness of the JtD intervention for 
people in the early stages of dementia. To meet this aim, 
the objectives are to:
1. Conduct an internal pilot RCT of the intervention to 
check the feasibility of rates of recruitment at scale.
2. Proceed to a full a pragmatic RCT evaluating the clini-
cal and cost-effectiveness of the JtD intervention.
3. Conduct fidelity checks regarding the delivery of the 
JtD intervention.
4. Undertake an embedded qualitative substudy to ex-
plore issues concerned with intervention delivery.
5. Identify how the intervention might be realistically de-
livered through services.
MEthods
trial design
The JtD trial is a pragmatic, two-arm, parallel group, indi-
vidually randomised RCT. It uses a superiority framework 
to deliver an intention-to-treat (ITT) comparison of the 
JtD intervention with usual care.
The trial includes three substudies. The first is a health 
economics evaluation using a cost-effectiveness analysis 
of the incremental cost per Quality Adjusted Life Year 
(QALY) of the JtD intervention compared with usual care.
The second substudy is a fidelity assessment as part 
of the process evaluation, using an intervention fidelity 
framework based on that identified by the Behaviour 
Change Consortium and National Institute for Health 
and Care Excellence (NICE).23 24
The third substudy is a qualitative study, part of the 
process evaluation, in line with Medical Research Council 
(MRC) guidance on developing and evaluating complex 
interventions.25 The qualitative substudy will involve semi-
structured interviews with participants, supporters, facili-
tators and supervisors.
randomisation, blinding and bias
To minimise bias, allocation will be concealed through 
the use of a centralised web-based randomisation service. 
The randomisation sequence will be stratified by delivery 
site and constrained by a fixed block size to ensure partic-
ipants are allocated evenly to each arm of the trial at each 
delivery site. Participants will be randomised in equal 
numbers to intervention and control arms. An unblind 
member of the research team who will not be conducting 
outcome assessments will enter the participants’ details 
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Figure 1 Participant flow through the study.
into the randomisation system and inform the relevant 
parties of the outcome.
Members of the Trial Steering Committee (TSC), study 
statisticians, health economists and outcome assessors 
will be blinded to treatment allocation while the trial 
is ongoing. For practical reasons linked to the provi-
sion of a centralised web-based randomisation service 
and the setup and delivery of the intervention groups, 
some members of the research team will not be blinded, 
including the Trial Manager and Chief Investigator. Due 
to the nature of the intervention, participants will not 
be blinded. If the outcome assessors know (or suspect) 
they have been unblinded, this will be recorded on an 
unblinding form.
We protect against facilitator bias where the same facili-
tators also provide usual care in two ways. The first is that 
usual care is limited and often restricted to NICE recom-
mended cognitive stimulation therapy which would not 
be readily influenced by training in delivery of JtD, as it 
follows a detailed and prescriptive session-by-session plan 
of group exercises which are facilitator-led. Other less 
common postdiagnostic services include Living Well with 
Dementia or memory groups, which do contain some 
features of JtD, but not enactment of learnt skills in the 
community or the mix of individual and group sessions JtD 
incorporates. The second way is that a proportion of the 
facilitators recruited will not deliver usual care, as approx-
imately 25% of facilitators are trained research staff. A 
further form of bias, that caused by cross-contamination 
of participants between the two study arms, is considered 
as unlikely as postdiagnostic services for people living with 
dementia are limited and cognitive stimulation therapy is 
more likely to be offered later in the dementia trajectory. 
Extended postdiagnostic follow-up is not common so it 
is unlikely participants from different study arms would 
meet at routine appointments and discuss involvement.
Participants
Persons with early-stage dementia will be approached to 
take part in the trial. A family member, friend or neigh-
bour that provides support to the study participant 
(referred to as the ‘supporter’) can be approached to 
take part in the trial, but only if invited to do so by the 
person with dementia. The study participant can also 
choose not to invite a supporter to take part in the trial 
and still take part. Participating supporters will automat-
ically be randomised to the same arm as the participant. 
See figure 1 for participant flow through the study.
Eligibility criteria
Participants will be eligible for the study if they:
1. have a diagnosis of any form of dementia, 
2. have a Mini Mental State Examination (MMSE) score 
of 18 or more, measured less than 2 months’ precon-
sent,
3. have capacity to make informed decisions, are living 
in the community in their own or sheltered accommo-
dation (those living in residential or nursing care are 
not eligible), 
4. are willing to attend the JtD intervention, 
5. are able to converse and communicate in English and
6. are not taking part in any other pharmacological 
or psychosocial intervention studies at the time of 
enrolment.
Supporters will be eligible to participate if they are aged 
18 years or over, are named by the person with dementia 
as their supporter, the person with dementia wishes them 
to take part, they can converse and communicate in 
English and have the ability to give informed consent.
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site selection and participant recruitment
The JtD trial will operate in England within 13 NHS trusts 
with specialist dementia services. The sites will be selected 
based on a convenience sample of locations clustered 
geographically around the north and midlands (for a list 
of sites, see study ISRCTN webpage26).
Previous studies involving persons with dementia have 
shown that recruiting participants to such studies can be 
challenging.27 To ensure sufficient numbers are recruited 
to the study, a number of recruitment pathways will be 
used: referral from clinical teams; mail-outs to eligible 
patients via primary or secondary care clinical teams; 
study promotion via posters and so on; third sector organ-
isations and the Join Dementia Research database. The 
research team will contact interested participants and 
send further information about the study. Clinical teams 
will check with the potential participants that they are 
willing to be approached by the research team before an 
approach is made.
To enable potential participants to make a direct 
approach to the research team, a reply card will be 
designed which can be completed, sealed and returned 
to the central research team who will then pass the infor-
mation on to relevant local site researchers. These reply 
cards will be distributed with information sheets at events 
including dementia cafes or posted as part of mail-outs 
to General Practitioners (GPs). Local promotions, for 
example, via posters in clinics or GPs, will include the 
telephone and email details of local researchers for direct 
contact to take place.
A consent and eligibility visit will be arranged if an indi-
vidual would like to take part where trained researchers 
will assess eligibility and request written informed consent.
Intervention
JtD is a manualised intervention consisting of 12 weekly 
facilitated groups with 8–12 participants with dementia, 
which take place over successive weeks. Each participant 
also receives four one-to-one sessions with one of the 
intervention facilitators, to pursue individual goals. The 
first one-to-one session takes place before the start of 
the group intervention, with the remaining three being 
scheduled during the 12 weeks and at locations and times 
agreed with the participant. The group aspect of inter-
vention should be delivered in a community venue.
The content of the JtD intervention involves:
1. Ways of thinking about dementia (what is dementia, ef-
fects on everyday life, challenging stereotypes, sharing 
coping strategies).
2. Keeping physically well (relationship between physical 
and mental well-being, embedding health activity in 
everyday life, diet).
3. Memory (strategies to aid memory, impact on everyday 
life and learning and practicing new techniques).
4. Keeping mentally well (relationships between anxiety 
and memory and dementia and stress).
5. Endings (celebration of achievements and how to 
move forward).
Participants are encouraged to select different topics 
from the manualised intervention and explore them with 
guidance and suggestions from facilitators. Participants 
are also able to suggest topics not within the manual. One 
essential component of the intervention is the enactment 
of activities, particularly in the community; 3 of the 12 
group meetings should be ‘out of venue’ activities. Partic-
ipants are able to invite a supporter to participate in the 
group aspect of the intervention during sessions 1, 6 and 
12 and in the individual sessions if the participant finds 
this helpful in achieving their goals.
The intervention should be facilitated by a minimum 
of two NHS staff who are experienced with working 
with people with dementia. Facilitators will normally be 
someone employed on Agenda for Change Bands 3–5. 
Facilitators must receive a 2-day training course prior to 
delivering the intervention. In some cases, for example, 
if they are a reserve facilitator, they may receive a short-
ened course supported by online resources created for 
this purpose. Facilitators will be supervised by a colleague 
experienced in supervision who has also attended the 
facilitator training and is of suitable seniority and expe-
rience. The supervisors themselves will be supervised 
by a member of the central study team who is a clinical 
psychologist and is experienced in the ‘train the trainer’ 
method.28
Patient and public involvement (PPI)
People living with dementia were involved in developing the 
content of JtD29 and in the feasibility study.22 The JtD TSC 
will include a member who is living with dementia. Addi-
tionally, an advisory group of people living with dementia 
(experts by experience) will meet at intervals throughout to 
provide input into study materials. We also plan to involve 
people living with dementia in some aspects of the qualita-
tive data analysis and in creating and delivering the study 
dissemination plans.
outcome measures
Outcomes were identified through a feasibility study 
which identified appropriate measures and tested their 
application.22 The burden of questionnaires was found to 
be acceptable.
The primary outcome is the Dementia Related 
Quality of Life (DEMQOL)30 31 measure at 8 months 
postrandomisation.
The secondary outcomes are:
 ► European Quality of Life-5 Dimensions, 5 level version 
(EQ-5D-5L).32 33
 ► Patient Health Questionnaire-9 (PHQ-9).34 35
 ► Generalised Anxiety Disorder-7 (GAD-7).36
 ► General Self-Efficacy Scale (GSE).37
 ► Diener’s Flourishing Scale (DFS).38
 ► Self-Management Ability Scale (SMAS).39
 ► Instrumental Activities of Daily Living (IADL).40
 ► Health and Social Care Resource Use Questionnaire 
(HSCRU).22
 ► Sense of Competency Questionnaire (SCQ).41 42
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Table 1 Outcome measures and time-points for collection
Measure
Participant Participating supporter
Eligibility 
and 
consent 
visit
Baseline
due <2 
months 
prior to the 
intervention 
start date
8 months
due <2 weeks before 
and <8 weeks 
after the 8 month 
anniversary of 
randomisation
12 months
due <2 weeks before 
and <8 weeks after the 
12 month anniversary 
of randomisation, if 
within study timelines
Baseline
same timings 
as participant 
baseline visit
8 months
same timings as 
participant 8 month 
visit
Capacity assessment ✓
Mini Mental State 
Examination
✓
Eligibility checklist ✓ ✓
Baseline demographics ✓ ✓
DEMQOL   ✓ ✓* ✓
EQ-5D-5L   ✓ ✓ ✓ ✓ ✓
PHQ-9   ✓ ✓ ✓ ✓
GAD-7   ✓ ✓
GSE   ✓ ✓
DFS   ✓ ✓
SMAS   ✓ ✓
IADL   ✓ ✓ ✓
HSCRU   ✓ ✓
SCQ   ✓ ✓
*Denotes the primary outcome measure.
DEMQOL, Dementia-Related Quality of Life; DFS, Diener’s Flourishing Scale; EQ-5D-5L, European Quality of Life-5 Dimensions, 5 level version 
; GAD-7, Generalised Anxiety Disorder-7; GSE, General Self-Efficacy Scale; HSCRU, Health and Social Care Resource Use Questionnaire; IADL, 
Instrumental Activities of Daily Living; PHQ-9, Patient Health Questionnaire-9; SCQ, Sense of Competency Questionnaire; SMAS, Self-Management 
Ability Scale.
See table 1 for further information on who completes 
which measures in the study. The outcome measures 
used were selected to measure the following key compo-
nents of the intervention: mental well-being or mood 
(DEMQOL, PHQ-9, GAD-7); building relationships and 
a sense of connectedness (DFS, SMAS); self-management 
(SMAS); belief that life is meaningful despite dementia 
(DEMQOL, GSE, DFS, SMAS) and Instrumental Activi-
ties of Daily Living (IADL) and strategies to maintain 
cognitive functioning (IADL). Additionally, they also 
support analysis of the cost-effectiveness of the interven-
tion (DEMQOL, EQ-5D-5L, HSCRU) and the partici-
pating supporters’ perceptions of competence (SCQ). 
Dementia-specific outcome measures are those recom-
mended for use across Europe and are selected for self 
rather than proxy completion.43 Non-dementia-specific 
outcome measures were selected if there was no appro-
priate dementia-specific measure available.
data collection
Data will be collected from all participants living with 
dementia at eligibility/consent, baseline, 8 and 12 months 
postrandomisation and from consented participating 
supporters at baseline and 8 months’ postrandomisation 
(see table 1). There is a reduced set of measures linked to 
the 12 month visit as we require limited further informa-
tion on quality of life and health and social care resource 
use at that time-point; the key outcome point is at 8 
months. The outcome measures will be interviewer-ad-
ministered at face-to-face visits by blinded outcome asses-
sors who have received training to deliver the measures 
to people living with dementia and their supporters. The 
follow-up outcome measures will be collected 2 weeks pre 
and 8 weeks post the date they are due. Participant reten-
tion will be promoted by regular communication with 
the participants and supporters through communication 
including newsletters and Christmas cards.
Visits to collect outcome data will be arranged with the 
participant by a researcher; in some cases, a participating 
supporter will assist with these arrangements. All visits 
will be conducted at a time and location most suitable 
for the participant. When we conduct the follow-ups, we 
will prioritise the importance of the measures in case the 
participant tires. We will offer a second visit if the partic-
ipant is tired or otherwise unable to complete the assess-
ments, which will be organised as soon as possible after 
the first. Participating supporters may not have the time 
or capacity to receive a face-to-face visit and follow-up 
outcome measures may therefore be collected from them 
over the telephone. Similarly, if a participant does not 
want a visit, a reduced set of outcome measures may be 
taken by telephone (prioritising collection of DEMQOL 
and telephone versions of HSCRU and EQ-5D-5L).
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Intervention attendance
Records will be kept of all attendances for each partici-
pant randomised to the intervention.
Intervention dropout and study withdrawal
If a participant decides to withdraw either from the inter-
vention or the study, this will be recorded. If the partic-
ipant just withdraws from the intervention, they will be 
followed-up unless they explicitly also withdraw consent 
for follow-up meetings for collection of outcomes (data 
up to this time will be included in the trial). If the partic-
ipant fully withdraws from the study, no further data will 
be collected.
Intervention costings
Information on the cost of facilitated group and indi-
vidual sessions will be collected including hire of local 
community venues, facilitator salaries and travel, refresh-
ments and other costs such as administration and mate-
rials used.
sample size
The primary outcome for the study is the mean DEMQOL 
score 8 months postrandomisation. Assuming a SD of 11 
points for the DEMQOL, a mean difference of 4 or more 
points is clinically and practically important.30 The sample 
size has been calculated to have a 90% power of detecting 
this 4 point difference (equivalent to a standardised effect 
size of 0.36) in group mean scores at 8 months as being 
statistically significant at 5% (two sided) level. As the JtD 
intervention is a facilitator led intervention with a group 
component, the outcomes of the participants in the same 
group with the same facilitators may be clustered. With no 
adjustment for clustering by facilitator, the target sample 
size would be 160 per arm with a total sample size of 320. 
We have assumed an average cluster size of 8 people 
with dementia per facilitated group and an intracluster 
correlation of 0.03; this will inflate the sample size by a 
design effect of 1.21, to 194 per group (388 total sample 
size) with valid primary outcome data. Assuming at least 
a 20% loss to follow-up the target sample size for the trial 
is to randomise to 243 participants in each arm (n=486).
data analysis
As JtD is a pragmatic parallel group randomised trial, 
with a usual care (control) arm, data will be reported and 
presented according to a revised CONSORT statement.44 
Statistical analysis will be performed on an ITT basis. All 
exploratory tests will be two-tailed with alpha=0.05. Base-
line demographics and quality of life data will be described 
and summarised overall and by treatment group.
The primary analysis will compare mean patient 
reported DEMQOL scores at 8 months postrandomi-
sation between the intervention (JtD) arm and control 
arms using a mixed effects linear regression model 
adjusted for DEMQOL baseline score and site and 
allowing for the clustering of the outcome by the JtD 
intervention.45–47 The trial is a partially nested design 
with comparison of a group therapy (JtD) with individual 
therapy with clustering in one (intervention) arm. Each 
person with dementia in the control group (unclustered 
arm) will be treated as a cluster (singleton) of size one. 
The cluster indicator will be treated as a random effect. 
A stratification variable used for randomisation (site) will 
be included as a fixed factor.48 A partially clustered mixed 
effects linear regression model with homoscedastic errors 
as well as a heteroscedasticity mixed effects linear regres-
sion model will also be considered to account for poten-
tial differential variability of outcomes between the two 
treatment groups. A 95% CI for the mean difference in 
DEMQOL scores between the intervention and control 
groups will be calculated together with the associated p 
value. A further adjusted analysis may also be performed 
depending on the observed degree of imbalance in 
baseline covariates (which are of potential prognostic 
importance) again using a mixed effects linear regression 
model. Additional covariates (of potential prognostic 
importance) include other baseline variables, such as age, 
gender, PHQ-9 and GAD-7. In the event that there are 
more than 10 couples (20 participants) living under the 
same roof from different households in the study, then 
the primary and secondary analyses will be changed to 
take into account the hierarchical or clustered nature of 
the data. A multilevel mixed effects model will be used; 
the random effects will be JtD intervention groups (top 
level) and couple/singles (lower level). Individual partic-
ipants who are not part of a couple will be treated as clus-
ters of size one.
Participants will be followed up for up to 12 months 
postrandomisation. Mean DEMQOL scores at 12 months 
follow-up will be compared as described for the primary 
outcome above.
For the primary outcome, the DEMQOL score at 8 
months follow-up, missing data will be imputed through 
a variety of methods including: regression and multiple 
imputation as part of a sensitivity analysis.
We will complement the ITT analysis of the primary 
outcome with a complier average causal effects analysis 
as a secondary analysis alongside the primary ITT anal-
ysis. Compliance will be defined as a binary variable with 
participants who attend at least 10 of the 16 JtD sessions 
(both individual and group sessions combined) regarded 
as being compliant.
There are no planned interim statistical analyses or 
formal stopping rules in relation to efficacy.
In terms of missing data, the primary analysis will be 
performed based on participants with available 8 month 
primary outcome data. Sensitivity analysis on the primary 
outcome will include multiple imputation using chained 
equations and regression imputation.
Secondary outcome measures
Secondary outcomes at 8 and 12 months postrandomi-
sation will be compared between the intervention and 
control groups using a mixed effects linear regression 
model as for the primary outcome. A 95% CI for the 
mean difference in this parameter between the treatment 
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groups will also be calculated together with the associated 
p value.
Outcome measures for the participating supporters at 
8 months will be compared between the intervention and 
control groups using a mixed effects linear regression 
model. The mean difference in outcome with associated 
95% CI and p value will be presented for: (1) the base-
line (specific to the secondary outcome) and site adjusted 
analysis and (2) adjusted analysis with additional covari-
ates in addition to (1).
Subgroup analysis
A subgroup analysis using a mixed effect linear regres-
sion model, with the primary outcome (DEMQOL) at 8 
months postrandomisation as the response will be carried 
out. We will use an interaction statistical test between 
the randomised intervention group and subgroup to 
directly examine the strength of evidence for the treat-
ment difference between the treatment groups varying 
between subgroups. Supporter involvement (yes or no) 
will be the only a priori defined subgroups to be consid-
ered for interaction test.
health economics evaluation
A trial-based economic evaluation will be undertaken 
of an ITT comparison of the costs and outcomes of the 
two trial arms. A cost-effectiveness analysis will be under-
taken of the incremental cost per QALYs of the JtD inter-
vention compared with usual care provided through 
NHS memory services. QALYs will be calculated using 
the EQ-5D-5L preference-based index administered at 
baseline, 8 and 12 months. A sensitivity analysis will be 
undertaken using utility values from the DEMQOL-U, 
which can be derived from responses to the DEMQOL 
questionnaire.30 The total cost of the intervention will 
be estimated at the individual participant level and will 
include the costs of providing the intervention and the 
subsequent consequences for the use of routine health 
and social care services. The average cost per attendance 
will be calculated and this estimate will be applied to the 
actual number of group and individual sessions that each 
participant attended.
The use of services by trial participants will be collected 
in detail using a HSCRU questionnaire administered 
at 8 and 12 months postrandomisation. Service use will 
be costed using the most recent National Reference 
Cost Data and Unit Costs of Health and Social Care.49 50 
Missing data will be dealt with using multiple imputa-
tion for EQ-5D-5L, DEMQOL-U and resource use data.51 
A random effects linear regression model, accounting 
for clustering, will be fitted, and the model will include 
baseline scores for EQ-5D-5L and baseline costs. The 
central analysis of mean incremental costs per QALY will 
be subjected to a full sensitivity analysis of key parame-
ters including the measure used to estimate QALYs and 
number of participants at the weekly sessions. A full prob-
abilistic sensitivity analysis will be performed to examine 
the probability of cost-effectiveness of the intervention 
for the NHS for different levels of costs and QALY gains.52
Process evaluation
The process evaluation has been designed to: (1) examine 
the factors that may influence the fidelity of intervention 
delivery and (2) explore its perceived impact and accept-
ability from user and provider perspectives. There are 
two strands to this, the fidelity assessment and qualitative 
interviews, explained below.
Fidelity assessment
The fidelity of intervention delivery as well as of the 
training and supervision received by facilitators will be 
assessed on the basis of criteria derived from the inter-
vention protocol and manual. Fidelity checks will adhere 
to a framework based on that identified by the Behaviour 
Change Consortium23 and NICE guidance on behaviour 
change.24 The fidelity assessment framework (adapted 
from Bellg et al 200423) will assess and monitor for the 
consistency, facilitator training (in terms of standardised 
delivery of training and skills acquisition for facilitators), 
intervention delivery (in terms of standardised delivery 
between intervention groups) and the receipt of the 
intervention by intervention group participants.
Training delivery and receipt of the facilitator training 
will be observed and rated by the same two researchers 
(the lead for fidelity and one other member of the 
research team) for inter-rater reliability using a bespoke 
Training observation checklist. To assess facilitator adherence 
to the manualised intervention and participant receipt of 
the intervention, a purposive selection of group meetings 
across sites will also be observed using a Group observation 
checklist which is based on the contents of the intervention 
and the training. Each selected group will be observed 
on two occasions to identify facilitator drift or changes in 
participant behaviour.
Frequencies will be used to determine the extent to which 
the training programme received by facilitators maintained 
fidelity to what was intended. Data will also be analysed to 
compare intervention delivery between and across sites to 
check for consistency. Inter-rater reliability between coders 
will be determined using the Kappa statistic.53 Similar 
methods have been used in previous studies.54
Qualitative interviews
An embedded qualitative substudy will explore the mech-
anisms of the intervention, for example, what elements 
of the intervention appear to support people to improve 
their self-management and well-being and what promotes 
good facilitation of the intervention.
Individual qualitative semistructured interviews will 
be conducted with a purposive sample of 20 participants 
(approximately 10%) from the intervention groups 
observed in the fidelity substudy and with approximately 
12 participating supporters, preferably supporters of 
participants who are also being interviewed. A participant 
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interview schedule and supporter interview schedule will 
be developed to cover the following themes:
 ► Range and nature of issues that influence experiences 
of taking part in the intervention.
 ► Factors that may influence the effectiveness, adoption 
and diffusion of this innovation in the future.
 ► Perceived skills and competencies required to facili-
tate the intervention.
 ► The barriers and facilitators to uptake and continued 
use.
 ► The effect of the intervention on living with dementia.
 ► The effect of the intervention on the experiences of 
supporting someone with dementia.
Semistructured interviews will also be conducted with 
approximately 20% of all facilitators and supervisors 
across the sites on completion of their delivery of the 
intervention. The sample will include a range of sites and 
facilitators with different levels of experience of deliv-
ering the intervention. A facilitator interview schedule 
and supervisor interview schedule will be created to cover 
the following themes:
 ► What issues promote the effectiveness of intervention 
facilitation.
 ► The skills and competencies required to facilitate the 
programme.
 ► The barriers and facilitators to its uptake and 
continued use.
 ► Factors that may mediate or moderate the effective-
ness of the intervention.
Researchers undertaking participant interviews will 
be trained to use enhanced methods of communication 
with people with dementia to try to ensure that mean-
ingful discussion takes place. Transcripts of interviews will 
undergo respondent validation.
Qualitative analysis
Framework analysis55 will be applied to all interview data.56 
For the purposes of reporting, confidentiality will be main-
tained by using unique participant identifiers and removing 
identifiable information. A thematic framework will be 
agreed by two researchers and an index developed for tran-
script coding. This will follow the five stages of framework 
analysis.55 Findings will be used to identify emergent factors 
that influence the uptake and impact of the intervention as 
well as explore potential explanations for the quantitative 
findings.56 Further analysis will also be undertaken to trian-
gulate the qualitative data (between facilitator/supervisor 
and participant/supporter interviews) as well as the fidelity 
and qualitative data in order to look for between source 
similarities and divergences. Analysis workshops will be 
held with people living with dementia and their supporters 
to respond to and help validate the initial qualitative anal-
ysis. The workshop outcomes will be used to refine the qual-
itative analysis.
data management, confidentiality and sharing
Sheffield Clinical Trials Research Unit (CTRU) will 
provide data management services. Data will be entered 
remotely on to a centralised web-based data capture system 
(Prospect) by university researchers and authorised staff 
at participating NHS sites. The case report form captures 
trial data and has been specifically designed for this 
trial. Access to prospect is controlled by usernames and 
encrypted passwords. Prospect provides a full electronic 
audit trail as well as validation features which will be used 
to monitor study data quality. The identity of participants 
will be protected by the removal of any identifiable data 
prior to dissemination of information, and no identifi-
able data will be transferred to the statistician or health 
economist. All participating NHS sites will be subject to 
data monitoring reviews to check data entry, consent and 
eligibility, among other items. The trial follows the UK 
Health Research Authority guidance on the General Data 
Protection Regulation57 and has implemented a privacy 
policy and transparency information appropriate to 
people living with dementia.
Data sharing
JtD trial data will be held and available for 5 years after the 
end of the trial (November 2019). JtD Trial Data will not 
be archived in a repository, instead data will be released 
on a case-by-case basis. We shall make data available to the 
scientific community with as few restrictions as feasible. 
Data access requests will be reviewed and authorised by 
a subcommittee of the Trial Management Group (TMG) 
during the trial and by the Sheffield CTRU after the trial 
has ended. Access requests will be considered against 
predetermined criteria and data sharing will only take 
place if this aligns with the consent provided by JtD partic-
ipants. Data will be anonymised prior to being shared.
Ethics, governance and safety
Ethical issues
There are two key ethical issues to take into account. 
The first is the potential need to break confidentiality 
where there is a risk of harm. We will request consent 
to contact the participant’s or supporter’s GP, or other 
health professional, in situations where researchers are 
concerned that there might be risk of harm. For example, 
two outcome measures used on the study may indicate 
a need to clinically treat anxiety (GAD-7) or depression 
(PHQ-9). Additionally, concerns regarding participant 
safety may also be raised at any stage of the study; for 
example, observed deterioration in mental or physical 
state of participants, safeguarding issues or of a risk to self 
or others. We will work alongside local Trust procedures 
to report any risks appropriately. Local site investigators 
with clinical backgrounds will be asked to provide advice 
when appropriate. The responsible healthcare profes-
sional or relevant PI will be able to recommend the with-
drawal of the participant if they feel it is appropriate. We 
will record all actions taken.
The second is the risk that during the trial, people with 
dementia may lose the capacity to consent to continuing 
participation. As part of the consent process, people with 
dementia will be asked to nominate a person to act as 
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a consultee we may contact in the event that they lose 
capacity during the trial. The consultee will be inde-
pendent from the study and can be a relative, friend or 
medical professional. All researchers will be provided 
with guidance and local training on identifying and 
dealing with capacity issues identified before or during 
8-month and 12-month follow-up visits. If at any point 
the participant indicates they do not wish to continue to 
take part in the trial, they will be withdrawn. If the person 
with dementia loses capacity during the trial, but indi-
cates they wish to remain in the study, the consultee will 
be asked to make a judgement, based on their existing 
and pre-existing knowledge of the person with dementia, 
about whether they would want to continue participation 
or not. If the consultee advises that the participant would 
wish to be withdrawn, the researchers will withdraw them 
from the study. If the consultee advises that the partic-
ipant would wish to stay taking part, even though they 
lack capacity, every effort will be made to accommodate 
this, for example, by reducing the number of outcome 
measures or using prompts or other means to help the 
participant complete the measures. We will record infor-
mation about the activation of the consultee pathway on 
the trial.
Governance
The trial is coordinated by the Sheffield CTRU on 
behalf of the Sponsor. The sponsor of the trial is Shef-
field Health and Social Care Foundation Trust, Fulwood 
House, Old Fulwood Road, Sheffield, S10 3TH. The JtD 
TMG contains project coapplicants, members of the data 
management team, the Sponsor, Trial Manager and other 
representatives and oversees the operation of the trial 
and enables communication throughout the Trial, for 
example, to disseminate protocol amendments. An inde-
pendent TSC, comprised of an independent statistician, 
PPI representative and a Senior Clinical Research Asso-
ciate, provides overall supervision of the trial, advises the 
CI, oversees protocol modifications, monitors the trial’s 
progress and if necessary closes the trial. An indepen-
dent Data Monitoring and Ethics Committee (DMEC) 
comprised of two independent statisticians and an Occu-
pational Therapist Clinical Researcher, reviews the trial 
protocol, monitors patient safety and advises the TSC if 
they feel the trial should be prematurely closed.
Safety
A serious adverse event (SAE) reporting system will be 
used on the Trial. Non-serious adverse events are not 
anticipated as a consequence of the intervention and will 
not be monitored.
An SAE either:
1. results in death,
2. is life-threatening (subject at immediate risk of death),
3. requires hospitalisation or prolongation of existing 
hospitalisation,
4. results in persistent or significant disability or incapac-
ity or
5. is otherwise considered medically significant by the 
investigator.
All SAEs will be assessed to see if they are related to the 
intervention or other trial procedures, and if they are the 
Sponsor and Research Ethics Committee will be imme-
diately informed. SAEs are periodically reported to the 
trial’s DMEC.
Additionally, we consider safety of the researchers to be 
extremely important and have developed a lone worker 
policy. The researcher must complete a form detailing 
information about any participant visits and their contact 
information and provide this to a ‘buddy’ who will ensure 
the safety of the researcher. The researcher must check 
in with the buddy before and after a visit finishes or 
the buddy will follow escalation procedures. Check-lists 
provide guidance on what to do before and during the 
visits, for example, ensuring phones are fully charged 
and being prepared to leave in an emergency if there are 
concerns about safety. A phrase is provided to enable the 
researcher to report an emergency during the visit. Guid-
ance is provided for general safe travelling, for example, 
to keep to well-lit paths and driveways.
dissemination
The results of this study will be communicated in relevant 
academic and professional journals, conferences and 
workshops and via websites and social media, ensuring 
reach to all stakeholders (people living with the condi-
tion, professionals, commissioners and academics). 
A short film will be created to illustrate experiences of 
participation from the perspectives of people living with 
the condition and those involved in delivery of the inter-
vention. The manualised intervention will be refined and 
made available on the website in an open access format 
and it is anticipated that this may be of interest to both 
primary care and memory services.
study status
At the time of submitting for publication, the study was 
collecting data. At the time of publication, the study is 
approaching database lock.
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